CNS Drugs

, Volume 22, Issue 12, pp 1021–1036 | Cite as

Hypnosedative-Induced Complex Behaviours

Incidence, Mechanisms and Management
Review Article

Abstract

A number of news items and case reports describing complex behaviours (e.g. sleep driving, sleep cooking, sleep eating, sleep conversations, sleep sex) associated with the use of hypnosedative medications have recently received considerable attention. Regulatory agencies examining these reports have subsequently issued warnings regarding the potential of hypnosedative agents to produce complex behaviours. Despite these warnings, little is known about the likelihood, presentation, treatment or prevention of hypnosedative-induced complex behaviours. The purpose of this review is to evaluate the published evidence regarding the clinical presentation, incidence, mechanism and management of sleep-related behaviours induced by nonbenzodiazepine receptor agonists (NBRAs).

Review of the literature identified ten published case reports of NBRA-induced complex behaviours involving 17 unique patients. Fifteen of the 17 patients described in the case reports had taken zolpidem, one had taken zaleplon and one had taken zopiclone. The complex behaviours most commonly reported were sleep eating, sleepwalking with object manipulation, sleep conversations, sleep driving, sleep sex and sleep shopping. Elevated serum concentrations resulting from increased medication dose or drug-drug interactions appeared to play a role in some but not all cases. Sex, age, previous medication exposure and concomitant disease states were not consistently found to be related to the risk of experiencing a medication-induced complex behaviour.

From a pharmacological standpoint, enhancement of GABA activity at GABAA receptors (particularly α1-GABAA receptors) is a possible mechanism for hypnosedative complex behaviours and amnesia. Evidence suggests that complex behaviour risk may increase with both dose and binding affinity at α1-GABAA receptors. The amnesia that accompanies complex behaviours is possibly due to inhibition of consolidation of short- to long-term memory, suggesting that the risk may extend to non-GABAergic hypnosedatives. While amnesia and GABA-related receptor actions are the most frequently discussed mechanisms for complex behaviours in the literature, they do not fully explain such behaviours, suggesting that other mechanisms and factors probably play a role.

A number of potential strategies are available to manage or prevent hypnosedative-induced complex behaviours. These include lowering the dose of, or stopping, the offending hypnosedative, switching to a different hypnosedative, treating patients with other classes of medications, using nonpharmacological treatment strategies for patients with sleep disorders, examining drug regimens for potential drug interactions that may predispose patients to experiencing complex behaviours, administering hypnosedative medications appropriately and selecting patients more carefully for treatment in terms of their likelihood of experiencing medication adverse effects.

References

  1. 1.
    US FDA. FDA requests label change for all sleep disorder drug products [online]. Available from URL: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01587.html [Accessed 2007 Jul 1]
  2. 2.
    Rosack J. Sleep medications to get stronger label warnings. Psychiatr News 2007; 42(7): 6–7Google Scholar
  3. 3.
    Canaday BR. Amnesia possibly associated with zolpidem administration. Pharmacotherapy 1996; 16: 687–9PubMedGoogle Scholar
  4. 4.
    Fava FA. Amnestic syndrome induced by zopiclone [letter]. Eur J Clin Pharmacol 1996; 50: 509PubMedCrossRefGoogle Scholar
  5. 5.
    Harazin J, Berigan TR. Zolpidem tartrate and somnambulism. Mil Med 1999; 164(9): 669–70PubMedGoogle Scholar
  6. 6.
    Morgenthaler TI, Silber MH. Amnestic sleep-related eating disorder associated with zolpidem. Sleep Med 2002; 3: 323–7PubMedCrossRefGoogle Scholar
  7. 7.
    Yanes Baonza M, Ferrer Garcia-Borras JM, Cabrera Majada A, et al. Sleep-walking linked to zolpidem [in Spanish; letter]. Aten Primaria 2003; 32(7): 438PubMedCrossRefGoogle Scholar
  8. 8.
    Sattar SP, Ramaswamy S, Bhatia SC, et al. Somnambulism due to probable interaction of valproic acid and zolpidem. Ann Pharmacother 2003; 37: 1429–33PubMedCrossRefGoogle Scholar
  9. 9.
    Liskow B, Pikalov A. Zaleplon overdose associated with sleepwalking and complex behavior. J Am Acad Child Adolesc Psychiatry 2004; 43: 927–8PubMedCrossRefGoogle Scholar
  10. 10.
    Kintz P, Villain M, Dumestre-Toulet V, et al. Drug-facilitated sexual assault and analytical toxicology: the role of LC-MS/ MS. A case involving zolpidem. J Clin Forensic Med 2005; 12: 36–41PubMedCrossRefGoogle Scholar
  11. 11.
    Yang W, Dollear M, Muthukrishnan SR. One rare side effect of zolpidem — sleepwalking: a case report. Arch Phys Med Rehabil 2005; 86: 1265–6PubMedCrossRefGoogle Scholar
  12. 12.
    Tsai MJ, Tsai YH, Huang YB. Compulsive activity and anterograde amnesia after zolpidem use. Clin Toxicol 2007; 45: 179–81CrossRefGoogle Scholar
  13. 13.
    Sanofi-aventis. Ambien CR®: prescribing information [online]. Available from URL: http://products.sanofi-aventis.us/ambien_cr/ambienCR.pdf [Accessed 2007 Aug 1]
  14. 14.
    Sanofi-aventis. Ambien: prescribing information [online]. Available from URL: http://products.sanofi-aventis.us/ambien/ambien.pdf [Accessed 2007 Aug 1]
  15. 15.
    King Pharmaceuticals. Sonata: prescribing information [online]. Available from URL: http://www.kingpharm.com/kingpharm/uploads/pdf_inserts/Sonata_PI_and_MedGuide.pdf [Accessed 2007 Aug 1]
  16. 16.
    Sepracor, Inc. Lunesta®: prescribing information [online]. Available from URL: http://www.lunesta.com/PostedApprovedLabelingText.pdf [Accessed 2007 Aug 1]
  17. 17.
    Takeda Pharmaceuticals America, Inc. Rozerem: prescribing information. [online]. Available from URL: http://www.rozerem.com/files/Rozerem_Prescribing_Information.pdf [Accessed 2007 Aug 1]
  18. 18.
    Barclay WR, Ayd Jr FJ, Callan JP, et al. Behavioural reactions to triazolam [letter]. Lancet 1979; 2(8150): 1018PubMedCrossRefGoogle Scholar
  19. 19.
    DeHart C. Adverse behavioral effects as manifestations of the major and minor tranquilizers. J Maine Med Assoc 1969; 60(2): 29–31PubMedGoogle Scholar
  20. 20.
    Simmer ED. A fugue-like state associated with diazepam use. Mil Med 1999; 164(6): 442–3PubMedGoogle Scholar
  21. 21.
    Terrell HB. Behavioral dyscontrol associated with combined use of alprazolam and ethanol [letter]. Am J Psychiatry 1988; 145(10): 1313PubMedGoogle Scholar
  22. 22.
    Weiner WJ, Goetz C, Nausleda PA, et al. Clonazepam and dopamine-related stereotyped behavior. Life Sci 1977; 21(7): 901–6PubMedCrossRefGoogle Scholar
  23. 23.
    Zisook S, DeVaul RA. Adverse behavioral effects of benzodiazepines. J Fam Pract 1977; 5(6): 963–6PubMedGoogle Scholar
  24. 24.
    Ansseau M, Poncelet PF, Schmitz D. High dose triazolam and anterograde amnesia [letter]. BMJ 1992; 304(6835): 1178PubMedCrossRefGoogle Scholar
  25. 25.
    Menkes DB. Triazolam-induced nocturnal bingeing with amnesia. Aust N Z J Psychiatry 1992; 26(2): 320–1PubMedCrossRefGoogle Scholar
  26. 26.
    Drake Jr ME. A case of parasomnia at REM sleep onset. J Clin Psychiatry 1987; 48(10): 414–5PubMedGoogle Scholar
  27. 27.
    Evans SM, Foltin RW, Fischman MW. Food “cravings” and the acute effects of alprazolam on food intake in women with premenstrual dysphoric disorder. Appetite 1999; 32(3): 331–49PubMedCrossRefGoogle Scholar
  28. 28.
    Schenck CH, Mahowald MW. A polysomnographically documented case of adult somnambulism with long-distance automobile driving and frequent nocturnal violence: parasomnia with continuing danger as a noninsane automatism? Sleep 1995; 18(9): 765–72PubMedGoogle Scholar
  29. 29.
    Schenck CH, Bundlie SR, Patterson AL, et al. Rapid eye movement sleep behavior disorder: a treatable parasomnia affecting older adults. JAMA 1987; 257(13): 1786–9PubMedCrossRefGoogle Scholar
  30. 30.
    Scharf MB, Fletcher K, Graham JP. Comparative amnestic effects of benzodiazepine hypnotic agents. J Clin Psychiatry 1988; 49: 134–7PubMedGoogle Scholar
  31. 31.
    Bixler EO, Kales A, Brubaker BH, et al. Adverse reactions to benzodiazepine hypnotics: spontaneous reporting system. Pharmacology 1987; 35: 286–300PubMedCrossRefGoogle Scholar
  32. 32.
    Barnard EA, Skolnick P, Olsen RW, et al. Subtypes of gamma-aminobutyric acid receptors: classification on the basis of subunit structure and receptor function. International Union of Pharmacology XV. Pharmacol Rev 1998; 50: 291–314Google Scholar
  33. 33.
    Sanger DJ. The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents. CNS Drugs 2004; 18 Suppl. 1: 9–15CrossRefGoogle Scholar
  34. 34.
    Rudolph U, Crestani F, Benke D, et al. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature 1999; 401: 796–800PubMedCrossRefGoogle Scholar
  35. 35.
    McKernan RM, Rosahl TW, Reynolds DS, et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor [alpha]l subtype. Nat Neurosci 2000; 3: 587–92PubMedCrossRefGoogle Scholar
  36. 36.
    Rowlett JK, Platt DM, Lelas S, et al. Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates. Proc Natl Acad Sci U S A 2005; 102(3): 915–20PubMedCrossRefGoogle Scholar
  37. 37.
    Griebel G, Perrault G, Tan S, et al. Comparison of the pharmacological properties of classical and novel BZ-omega receptor ligands. Behav Pharmacol 1999; 10: 483–95PubMedCrossRefGoogle Scholar
  38. 38.
    Damgen K, Luddens H. Zaleplon displays a selectivity to recombinant GABAA receptors different from zolpidem, zopiclone and benzodiazepines. Neurosci Res Commun 1999; 25: 139–48CrossRefGoogle Scholar
  39. 39.
    Holm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 2000; 59: 865–89PubMedCrossRefGoogle Scholar
  40. 40.
    Perrault G, Morel E, Sanger DJ, et al. Differences in pharmacological profiles of a new generation of benzodiazepine and non-benzodiazepine hypnotics. Eur J Pharmacol 1990; 187: 487–94PubMedCrossRefGoogle Scholar
  41. 41.
    Huang MC, Lin HY, Chen CH. Dependence on zolpidem. Psychiatry Clin Neurosci 2007; 61: 207–8PubMedCrossRefGoogle Scholar
  42. 42.
    Sanna E, Busonero F, Talani G, et al. Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA(A) receptor subtypes. Eur J Pharmacol 2002; 451: 103–10PubMedCrossRefGoogle Scholar
  43. 43.
    McKay AC, Dundee JW. Effect of oral benzodiazepines on memory. Br J Anaesth 1980; 52: 1247–57PubMedCrossRefGoogle Scholar
  44. 44.
    Mintzer MZ, Griffiths RR. Triazolam and zolpidem: effects on human memory and attentional processes. Psychopharmacology 1999; 144: 8–19PubMedCrossRefGoogle Scholar
  45. 45.
    O’Boyle CA. Benzodiazepine-induced amnesia and anaesthetic practice: a review. Psychopharmacol Ser 1988; 6: 146–65PubMedGoogle Scholar
  46. 46.
    Lloyd GK, Danielou G, Thuret F. The activity of zolpidem and other hypnotics within the gamma-aminobutyric acid (GABAA) receptor supramolecular complex, as determined by 35S-t-butylbicyclophosphorothionate (35S-TBPS) binding to rat cerebral cortex membranes. J Pharmacol Exp Ther 1990; 255: 690–6PubMedGoogle Scholar
  47. 47.
    Benavides J, Peny B, Ruano D, et al. Comparative autoradiographic distribution of central omega (benzodiazepine) modulatory site subtypes with high, intermediate and low affinity for zolpidem and alpidem. Brain Res 1993; 604(1–2): 240–50PubMedCrossRefGoogle Scholar
  48. 48.
    Schmid L, Bottlaender M, Fuseau C, et al. Zolpidem displays heterogeneity in its binding to the nonhuman primate benzodiazepine receptor in vivo. J Neurochem 1995; 65: 1880–6PubMedCrossRefGoogle Scholar
  49. 49.
    Roehrs T, Merlotti L, Zorick F, et al. Sedative, memory, and performance effects of hypnotics. Psychopharmacology 1994; 116: 130–4PubMedCrossRefGoogle Scholar
  50. 50.
    Cherkin A, Harroun P. Anesthesia and memory processes. Anesthesiology 1971; 34: 469–74PubMedCrossRefGoogle Scholar
  51. 51.
    Goulle JP, Anger JP. Drug-facilitated robbery or sexual assault: problems associated with amnesia. Ther Drug Monit 2004; 26: 206–10PubMedCrossRefGoogle Scholar
  52. 52.
    Cajochen C. TAK-375 Takeda. Curr Opin Investig Drugs 2005; 6: 114–21PubMedGoogle Scholar
  53. 53.
    Kato K, Hirai K, Nishiyama K, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 2005; 48: 301–10PubMedCrossRefGoogle Scholar
  54. 54.
    Turek FW, Gillette MU. Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists. Sleep Med 2004; 5: 523–32PubMedCrossRefGoogle Scholar
  55. 55.
    Witt-Enderby PA, Bennett J, Jarzynka MJ, et al. Melatonin receptors and their regulation: biochemical and structural mechanisms. Life Sci 2003; 72: 2183–98PubMedCrossRefGoogle Scholar
  56. 56.
    McGechan A, Wellington K. Ramelteon. CNS Drugs 2005; 19: 1057–65PubMedCrossRefGoogle Scholar
  57. 57.
    Delafuente JC. Understanding and preventing drug interactions in elderly patients. Crit Rev Oncol Hematol 2003; 48: 133–43PubMedCrossRefGoogle Scholar
  58. 58.
    Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38: 41–57PubMedCrossRefGoogle Scholar
  59. 59.
    Becquemont L, Mouajjah S, Escaffre O, et al. Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism. Drug Metab Dispos 1999; 27: 1068–73PubMedGoogle Scholar
  60. 60.
    Goa KL, Heel RC. Zopiclone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic. Drugs 1986; 32: 48–65PubMedCrossRefGoogle Scholar
  61. 61.
    Pichard L, Gillet G, Bonfils C, et al. Oxidative metabolism of zolpidem by human liver cytochrome P450S. Drug Metab Dispos 1995; 23: 1253–62PubMedGoogle Scholar
  62. 62.
    Salva P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem: therapeutic implications. Clin Pharmacokinet 1995; 29: 142–53PubMedCrossRefGoogle Scholar
  63. 63.
    Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. Clin Pharmacol Ther 1998; 64: 661–71PubMedCrossRefGoogle Scholar
  64. 64.
    Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Differential impairment of triazolam and zolpidem clearance by ritonavir. J Acquir Immune Defic Syndr 2000; 24: 129–36PubMedGoogle Scholar
  65. 65.
    Drover D, Lemmens H, Naidu S, et al. Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem. Clin Ther 2000; 22: 1443–61PubMedCrossRefGoogle Scholar
  66. 66.
    Greenblatt DJ, Harmatz JS, von Moltke LL, et al. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. Clin Pharmacol Ther 1998; 64: 553–61PubMedCrossRefGoogle Scholar
  67. 67.
    Karim A, Tolbert D, Cao C. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol 2006; 46: 140–8PubMedCrossRefGoogle Scholar
  68. 68.
    He P, Court MH, Greenblatt DJ, et al. Factors influencing midazolam hydroxylation activity in human liver microsomes. Drug Metab Dispos 2006; 34(7): 1198–207PubMedCrossRefGoogle Scholar
  69. 69.
    Lepper ER, Baker SD, Permenter M, et al. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. Clin Cancer Res 2005; 11(20): 7398–404PubMedCrossRefGoogle Scholar
  70. 70.
    Hu YF, Qiu W, Liu ZQ, et al. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation. Clin Exp Pharmacol Physiol 2006; 33(11): 1093–8PubMedCrossRefGoogle Scholar
  71. 71.
    Op den Buijsch RA, Christiaans MH, Stolk LM, et al. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundam Clin Pharmacol 2007; 21(4): 427–35PubMedCrossRefGoogle Scholar
  72. 72.
    Fukasawa T, Suzuki A, Otani K. Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. J Clin Pharm Ther 2007; 32(4): 333–41PubMedCrossRefGoogle Scholar
  73. 73.
    Aranko K, Seppala T, Pellinen J, et al. Interaction of diazepam or lorazepam with alcohol: psychomotor effects and bioas-sayed serum levels after single and repeated doses. Eur J Clin Pharmacol 1985; 28: 559–65PubMedCrossRefGoogle Scholar
  74. 74.
    van Steveninck AL, Gieschke R, Schoemaker RC, et al. Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol. Br J Clin Pharmacol 1996; 41: 565–73PubMedCrossRefGoogle Scholar
  75. 75.
    Lovinger DM, Homanics GE. Tonic for what ails us? High-affinity GABAA receptors and alcohol. Alcohol 2007; 41: 139–43PubMedCrossRefGoogle Scholar
  76. 76.
    Cysneiros RM, Farkas D, Harmatz JS, et al. Pharmacokinetic and pharmacodynamic interactions between zolpidem and caffeine. Clin Pharmacol Ther 2007; 82: 54–62PubMedCrossRefGoogle Scholar
  77. 77.
    National Institutes of Health. NIH state-of-the-science conference statement on manifestations and management of chronic insomnia in adults [online]. Available from URL: http://consensus.nih.gov/2005/2005InsomniaSOS026html.htm [Accessed 2007 Jul 1]
  78. 78.
    Sivertsen B, Omvik S, Pallesen S, et al. Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial. JAMA 2006; 295: 2851–8PubMedCrossRefGoogle Scholar
  79. 79.
    Toner LC, Tsambiras BM, Catalano G, et al. Central nervous system side effects associated with zolpidem treatment. Clin Neuropharmacol 2000; 23: 54–8PubMedCrossRefGoogle Scholar
  80. 80.
    Kito S, Koga Y. Visual hallucinations and amnesia associated with zolpidem triggered by fluvoxamine: a possible interaction. Int Psychogeriatr 2006; 18: 749–51PubMedCrossRefGoogle Scholar
  81. 81.
    Sanofi-aventis. Ambien and Ambien CR dear healthcare professional letter, 2007 March [online]. Available from URL: http://www.ambiencr.com/docs/pdf/AmbienIRCRDHCPletter.pdf [Accessed 2007 Sep 30]

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  1. 1.Wingate University School of PharmacyWingateUSA
  2. 2.Carolinas Medical Center-NorthEastConcordUSA

Personalised recommendations